Evolution of the Average Target: DSM-Firmenich

Evolution of the Target Price: DSM-Firmenich

Changes in Analyst Recommendations: DSM-Firmenich

6ad5fc01a591406.7oX1nnUmqaXjVz4RBMWuLl87dEmi3qEI6yKVZnLryPE.rM-jpxFRmIiaY2x4fPzWaA9CEz3op-1bs3rKNkC5n8Wh6J34KlaZx5Q7Cg~cd1186eb601d5c6544f558df4d04f60f
08-12 Kempen Downgrades DSM-Firmenich to Sell, Boosts PT MT
08-10 Oddo BHF Boosts DSM-Firmenich PT, Maintains Outperform Rating MT
08-06 Equita SIM Downgrades DSM-Firmenich to Hold, Raises PT MT
07-30 DSM-Firmenich: Volume inflection validated the strategy Alphavalue
06-19 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
06-09 AlphaValue/Baader Europe Upgrades DSM-Firmenich to Add, Lifts PT MT
06-08 Goldman Sachs Downgrades DSM-Firmenich to Sell, Cuts PT MT
05-22 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
05-22 Swiss stocks - Factors to watch on May 22 RE
05-06 DSM-Firmenich: Volumes deliver, margin to follow Alphavalue
04-28 KBC Securities weighs in on DSM-Firmenich divestment Zonebourse
03-18 KBC Securities Still Positive on DSM-Firmenich Zonebourse
03-17 Sulfur and methanol prices soar on Middle East conflict Alphavalue
03-13 DSM-Firmenich ready to step up the pace and hit its mid-term targets Zonebourse
03-12 DSM-Firmenich: The story moves from restructuring to delivery Alphavalue
03-11 Kempen Downgrades DSM-Firmenich to Neutral, Cuts PT MT
03-04 Middle East tensions intensify pessimism in chemicals Alphavalue
02-26 AlphaValue/Baader Europe Adjusts Rating, Estimates for DSM-Firmenich on Sale of Animal Nutrition, Health Unit MT
02-25 DSM-Firmenich: ANH Divestment at a Discount May Unlock Growth Potential Alphavalue
02-13 Kepler Cheuvreux Downgrades DSM-Firmenich to Hold, Cuts PT MT
02-12 DSM-Firmenich: Profitability disappoints in FY25 Alphavalue
02-09 DSM-FIRMENICH : Jefferies reaffirms its Buy rating ZD
12-30 Berenberg Reduces DSM-Firmenich PT, Keeps Buy Rating MT
12-30 Berenberg Expects DSM-Firmenich to Retain Minority Stake in Vitamins Business Amid 'Protracted' Deal Talks MT
11-13 Barclays Downgrades DSM-Firmenich to Equalweight, Cuts PT MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+2.32%
+8.69%
+0.97%
+29.8%
+3.17%
+16.19%
+11.8%
-1.82%
Average +8.89%
Weighted average by Cap. +5.27%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
92.56EUR
Average target price
90.88EUR
Spread / Average Target
-1.82%
High Price Target
106.00EUR
Spread / Highest target
+14.52%
Low Price Target
67.00EUR
Spread / Lowest Target
-27.61%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

ODDO BHF
Equita SIM
alphavalue Théodore Duval-Segard
AlphaValue/Baader Europe
Goldman Sachs
Kempen
Kepler Cheuvreux
JEFFERIES Chris Counihan
Berenberg Bank
Barclays
Deutsche Bank Research
BNP Paribas
Stifel Nicolaus
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
92.56EUR
Average target price
90.88EUR
Spread / Average Target
-1.82%

Quarterly revenue - Rate of surprise